secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2021-11-29T23:59:59+00:00
Accession:  0001213900-21-062296
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus shareholders approve reverse split authorization and 2021 stock plan
---------------------------------------------------------------------------

- Reverse stock split authorization approved: 29,399,449 for, 540,130 against, 90,183 withheld.
- 2021 Stock Incentive Plan approved: 25,609,777 for, 433,820 against, 36,796 withheld.
- Seven directors elected: Yutaka Niihara, Willis C. Lee, Robert Dickey IV, Masaharu Osato, Jane Pine Wood, Wei Peu Zen, Alfred Lui.
- Advisory say-on-pay vote approved: 25,543,032 for, 497,065 against; board set frequency at every three years.
- Baker Tilly US, LLP ratified as independent auditor for FY2021: 29,935,626 for, 44,800 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390021062296/0001213900-21-062296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390021062296/ea151382-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-062296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer